Chronic inflammation in venous leg ulcer - Problems and perspectives

Central-European Journal of Immunology

Volumn 34, Issue 4, 2009, Pages 247-251

  Litwiniuk, Małgorzata ^a   Grzela, Tomasz ^a   Brawura Biskupski Samaha, Robert ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Chronic venous ulcer; Inflammation; Wound healing

Indexed keywords

CHRONIC INFLAMMATION; HUMAN; LEG ULCER; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS; VEIN INSUFFICIENCY; WOUND CARE;

EID: 75349088243     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Etufugh CN, Phillips TJ (2007): Venous ulcers. Clin Dermatol 25: 121-130.
2. th birthday. Eur J Vasc Endovasc Surg 26: 176-178.
3. Mekkes JR, Loots MAM, Van der Wal AC, Box JD (2003): Causes, investigation and a treatment of leg ulceration. Br J Dermatol 148: 388-401.
4. Ruckley C (1997): Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 46: 67-69.
5. Margolis DJ, Knauss J, Bilker W (2004): Medical conditions associated with venous leg ulcers. Br J Dermatol 150: 267-273.
6. Bergquist D, Lindholm C, Nelzen O (1999): Chronic leg ulcers: the impact of venous disease. J Vasc Surg 29: 752-755.
7. Mustoe TA, O'Shaughnessy K, Kloeters O (2006): Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg 117: S35-S41.
8. Milic DJ, Zivic SS, Bogdanovic DC et al. (2009): Risk factors related to the failure of venous leg ulcers to heal with compression treatment. J Vasc Surg 49: 1242-1247.
9. Schierle CF, De la Garza M, Mustoe TA, Galiano RD (2009): Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Rep Reg 17: 354-359.
10. Dowd SE, Sun Y, Secor PR et al. (2008): Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiology 8: 43.
11. Wysocki AB, Staiano-Coico L, Grinell F (1993): Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 101: 64-68.
12. Trengove NJ, Stacey MC, MacAuley S et al. (1999): Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Reg 7: 442-452.
13. Gao Z, Tseng CH, Pei Z, Blaser MJ (2007): Molecular analysis of human forearm superficial skin bacterial biota. Proc Natl Acad Sci USA 104: 2927-2932.
14. Edwards R, Harding KG (2004): Bacteria and wound healing. Curr Opin Infect Dis 17: 91-96.
15. Bjarnsholt T, Kirketerp-Møller K, Jensen PO et al. (2008): Why chronic wounds will not heal: a novel hypothesis. Wound Rep Reg 16: 2-10.
16. James GA, Swogger E, Wolcott R et al. (2008): Biofilms in chronic wounds. Wound Rep Reg 16: 37-44.
17. Gjodsbol K, Christensen JJ, Karlsmark T et al. (2006): Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 3: 225-231.
18. Nivens DE, Ohman DE, Williams J, Franklin MJ (2001): Role of alginate and its O acetylation in formation of pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol 183: 1047-1057.
19. Simpson JA, Smith SE, Dean RT (1989): Scavenging by alginate of free radicals released by macrophages. Free Radic Biol Med 6: 347-353.
20. Jensen PO, Bjarnsholt T, Phipps R et al. (2007): Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorumsensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153: 1329-1338.
21. Anvar H, van Biesen T, Dasqupta M et al. (1989): Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrob Agents Chemother 33: 1824-1826.
22. Hassett DJ, Ma JF, Elkins JG et al. (1999): Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol 34: 1082-1093.
23. Rasmussen K, Lewandowski Z (1998): Microelectrode measurements of local mass transport rates in heterogeneous biofilms. Biotechnol Bioeng 59: 302-309.
24. Bradshaw DJ, Marsh PD, Watson GK, Allison C (1998): Role of Fusobacterium nucleatum and coaggregation in anaerobe survival in planktonic and biofilm oral microbial communities during aeration. Infect Immun 66: 4729-4732.
25. Wall IB, Davies CE, Hill KE et al. (2002): Potential role of anaerobic cocci in impaired human wound healing. Wound Rep Reg 10: 346-353.
26. Estrela AB, Heck MG, Abraham WR (2009): Novel approaches to control biofilm infections. Curr Med Chem 16: 1512-1530.
27. Hentzer M, Riedel K, Rasmussen TB et al. (2002): Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148: 87-102.
28. Thomas PRS, Nash GB, Dormandy JA (1988): White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J 296: 1693-1695.
29. Carlos TM, Harlan JM (1994): Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101.
30. Pascarella L, Penn A, Schmid-Schonbein GW (2005): Venous hypertension and the inflammatory cascade: major manifestations and trigger mechanisms. Angiology 56: 3-10.
31. Saharay M, Shields DA, Porter JB et al. (1997): Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 25: 265-273.
32. Saharay M, Shields DA, Georgiannos SN et al. (1998): Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 15: 342-349.
33. Mulivor AV, Lipowsky HH (2002): Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 283: H1282-H1291.
34. Meissner MH, Gloviczki P, Bergan J et al. (2007): Primary chronic venous disorders. J Vasc Surg 46: 54S-67S.
35. Jacob T, Hingorani A, Ascher E (2005): Overexpression of transforming growth factor beta1 correlates with increased synthesis of nitric oxide synthase in varicose veins. J Vasc Surg 41: 523-530.
36. Schmidt A, Geigenmueller S, Voelker W et al. (2003): Exogenous nitric oxide causes overexpression of TGF-beta1 and overproduction of extracellular matrix in human coronary smooth muscle cells. Cardiovasc Res 58: 671-678.
37. Vodovotz Y, Chesler L, Chong H et al. (1999): Regulation of transforming growth factor β1 by nitric oxide. Cancer Res 59: 2142-2149.
38. Kowalewski R, Sobolewski K, Wolanska M, Gacko M (2004): Matrix metalloproteinases in the vein wall. Int Angiol 23: 164-169.
39. Trengove NJ, Stacey MC, MacAuley S et al. (1999): Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Reg 7: 442-452.
40. Norgauer J, Hildenbrand T, Idzko M et al. (2002): Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 147: 1180-1186.
41. Saito S, Trovato MJ, You R et al. (2001): Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34: 930-938.
42. Ogawa K, Chen F, Kuang C, Chen Y (2004): Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem J 381: 413-422.
43. Mwaura B, Mahendran B, Hynes N et al. (2006): The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 31: 306-310.
44. Rayment EA, Upton Z, Shooter GK (2008): Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 158: 951-961.
45. Ladwig GP, Robson MC, Liu R et al. (2002): Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Rep Reg 10: 26-37.
46. Wysocki AB, Kusakabe AO, Chang S, Tuan TL (1999): Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Rep Reg 7: 154-165.
47. Grzela K, Lazarczyk M, Dziunycz P et al. (2004): Molecular therapy versus standard treatment in allergy. Int J Mol Med 14: 3-22.
48. Agren SM, Werthen M (2007): The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Int J Low Extrem Wounds 6: 82-97.
49. Saari H, Konttinen YT (1989): Determination of synovial fluid hyaluronate concentration and polymerization by high performance liquid chromatography. Ann Rheum Dis 48: 565-570.
50. Noble PW (2002): Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 21: 25-29.
51. Frost GI, Csoka TB, Stern R (1996): The hyaluronidases: a chemical, biological and clinical overview. Trends Glycosci Glycotech 8: 419-434.
52. Moseley R, Waddington RJ, Embery G (1997): Degradation of glycosaminoglycans by reactive oxygen species derived from stimulated polymorphonuclear leukocytes. Biochim Biophys Acta 1362: 221-231.
53. Mascarenhas MM, Day RM, Ochoa CD et al. (2004): Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression. Am J Respir Cell Mol Biol 30: 51-60.
54. Jiang D, Liang J, Noble PW (2007): Hyaluronan in Tissue Injury and Repair. Annu Rev Cell Dev Biol 23: 435-461.
55. Termeer C, Benedix F, Sleeman J et al. (2002): Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195: 99-111.
56. Taylor KR, Trowbridge JM, Rudisill JA et al. (2004): Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 279: 17079-17084.
57. Fieber C, Baumann P, Vallon R et al. (2004): Hyaluronanoligosachcaride- induced transcription of metalloproteases. J Cell Sci 117: 359-367.
58. Forrester JV, Balazs EA (1980): Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 40: 435-446.
59. Neumann A, Schinzel R, Palm R et al. (1999): High molecular weight hyaluronic acid inhibits advanced glycation endproductinduced NF-kappaB activation and cytokine expression. FEBS Lett 453: 283-287.
60. Krasinski R, Tchorzewski H (2007): Hyaluronan-mediated regulation of inflammation. Postepy Hig Med Dosw 61: 683-689.